Should I buy or sell Laboratory Co. of America stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LH shares. View LH analyst ratings or view top-rated stocks .

What is Laboratory Co. of America's stock price target for 2024?

10 analysts have issued 12-month price targets for Laboratory Co. of America's shares. Their LH share price targets range from $210.00 to $270.00. On average, they predict the company's share price to reach $243.67 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price. View analysts price targets for LH or view top-rated stocks among Wall Street analysts .

How have LH shares performed in 2023?

Laboratory Co. of America's stock was trading at $235.48 at the beginning of the year. Since then, LH stock has decreased by 7.0% and is now trading at $218.97. View the best growth stocks for 2023 here .

Are investors shorting Laboratory Co. of America?

Laboratory Co. of America saw a decline in short interest during the month of October. As of October 31st, there was short interest totaling 3,280,000 shares, a decline of 14.4% from the October 15th total of 3,830,000 shares. Based on an average trading volume of 833,500 shares, the short-interest ratio is currently 3.9 days. Approximately 3.9% of the shares of the company are sold short. View Laboratory Co. of America's Short Interest .

When is Laboratory Co. of America's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024. View our LH earnings forecast .

How were Laboratory Co. of America's earnings last quarter?

Laboratory Co. of America Holdings (NYSE:LH) posted its quarterly earnings results on Thursday, October, 26th. The medical research company reported $3.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.37 by $0.01. The medical research company earned $3.06 billion during the quarter, compared to analyst estimates of $2.99 billion. Laboratory Co. of America had a trailing twelve-month return on equity of 14.09% and a net margin of 4.88%. The company's revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.68 earnings per share. Read the conference call transcript .

How often does Laboratory Co. of America pay dividends? What is the dividend yield for Laboratory Co. of America?

Laboratory Co. of America declared a quarterly dividend on Thursday, October 12th. Shareholders of record on Wednesday, November 8th will be paid a dividend of $0.72 per share on Tuesday, December 12th. This represents a $2.88 annualized dividend and a yield of 1.32%. The ex-dividend date is Tuesday, November 7th. Read our dividend analysis for LH .

Is Laboratory Co. of America a good dividend stock?

Laboratory Co. of America (NYSE:LH) pays an annual dividend of $2.88 per share and currently has a dividend yield of 1.35%. The dividend payout ratio is 38.50%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LH will have a dividend payout ratio of 19.82% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for LH .

What ETFs hold Laboratory Co. of America's stock?

ETFs with the largest weight of Laboratory Co. of America (NYSE:LH) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM) , Cambiar Aggressive Value ETF (CAMX) , Global X Telemedicine & Digital Health ETF (EDOC) , iShares U.S. Healthcare Providers ETF (IHF) , VictoryShares THB Mid Cap ESG ETF (MDCP) , BlackRock Large Cap Value ETF (BLCV) , Strategas Global Policy Opportunities ETF (SAGP) and Thrivent Small-Mid Cap ESG ETF (TSME) .

What guidance has Laboratory Co. of America issued on next quarter's earnings?

Laboratory Co. of America updated its FY 2026 earnings guidance on Friday, September, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $14.00B-.

What is Adam Schechter's approval rating as Laboratory Co. of America's CEO?

143 employees have rated Laboratory Co. of America Chief Executive Officer Adam Schechter on Glassdoor.com . Adam Schechter has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Laboratory Co. of America own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Co. of America investors own include Gilead Sciences (GILD) , Micron Technology (MU) , Intel (INTC) , Pfizer (PFE) , Johnson & Johnson (JNJ) , NVIDIA (NVDA) , Abbott Laboratories (abt) , AbbVie (ABBV) , Alibaba Group (BABA) and Amgen (AMGN) .

Who are Laboratory Co. of America's major shareholders?

Laboratory Co. of America's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (2.93%), Morgan Stanley (2.61%), Lazard Asset Management LLC (2.61%), Diamond Hill Capital Management Inc. (1.51%), Northern Trust Corp (1.33%) and FMR LLC (1.26%). Insiders that own company stock include Amy B Summy , Brian J Caveney , Der Vaart Sandra D Van , Dwight Gary Gilliland , Glenn A Eisenberg , Jean-Luc Belingard , Kerrii B Anderson , Mark S Schroeder , Paul R Kirchgraber , Peter J Wilkinson , Peter M Neupert and R Sanders Williams . View institutional ownership trends .

How do I buy shares of Laboratory Co. of America?

Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Laboratory Co. of America have any subsidiaries?

The following companies are subsidiares of Laboratory Co. of America: 1957285 Ontario Inc. dba Quality Underwriting Services, 2089729 Ontario Inc., 2248848 Ontario Inc., 3065619 Nova Scotia Company, 3257959 Nova Scotia Company, 8165335 Canada Inc., 8348596 Canada Inc., 896988 Ontario Limited, 9279-3280 Quebec Inc., Accupath Diagnostic Laboratories Inc., Assets of Pathology Inc, Beacon LBS IPA Inc., Beacon Laboratory Benefit Solutions Inc., CannAmm GP Inc., CannAmm Limited Partnership, Center for Disease Detection International, Center for Disease Detection LLC, Centrex Clinical Laboratories Inc., Chiltern, Clearstone Central Laboratories (U.S.) Inc., Clearstone Holdings (International) Ltd., Clinical Outreach Laboratory Services, Clipper Holdings Inc., Colorado Coagulation Consultants Inc., Colorado Laboratory Services LLC, Correlagen Diagnostics Inc., Covance Inc., Curalab Inc., Cytometry Associates Inc., Czura Thornton (Hong Kong) Limited, DCL Acquisition Inc., DCL Medical Laboratories LLC, DCL Sub LLC, DIANON Systems Inc., DL Holdings Limited Partnership, Decision Diagnostics L.L.C. (aka DaVinici/Medicorp LLC), Diagnostic Services Inc., DynaLifeDX, Dynacare - Gamma Laboratory Partnership, Dynacare Company, Dynacare G.P. Inc., Dynacare Holdco LLC, Dynacare Laboratories Inc., Dynacare Laboratories Limited Partnership, Dynacare Northwest Inc., Dynacare Realty Inc., DynalifeDX Infrastructure Inc., Envigo's nonclinical contract research services business, Esoterix Genetic Counseling LLC, Esoterix Genetic Laboratories LLC, Esoterix Inc., Execmed Health Services Inc., FirstSource Laboratory Solutions Inc., GDML Medical Laboratories Inc, Gamma Dynacare Central Medical Laboratories GP Inc., Gamma Dynacare Central Medical Laboratory Limited Partnership, HHLA Lab-In-An-Envelope LLC, Health Testing Centers Inc., Health Trans Services Inc., Home Healthcare Laboratory of America LLC, IDX Pathology Inc., Impact Genetics Corporation, Impact Genetics Inc., Kaleida LabCorp LLC, Lab Delivery Service of New York City Inc., LabCorp BVBA, LabCorp Belgium Holdings Inc., LabCorp Central Laboratories (Canada) Inc., LabCorp Central Laboratories (China) Inc., LabCorp Colorado Inc., LabCorp Development Company, LabCorp Employer Services Inc., LabCorp Health System Diagnostics LLC, LabCorp Indiana Inc., LabCorp Japan G.K., LabCorp Limited, LabCorp Michigan Inc., LabCorp Nebraska Inc., LabCorp Neon Ltd., LabCorp Neon Switzerland S.à.r.l., LabCorp Specialty Testing Billing Service Inc., LabCorp Specialty Testing Group Inc., LabCorp Staffing Solutions Inc., LabCorp Tennessee LLC, LabCorp UK Holdings Ltd., LabWest Inc., Laboratoire Bio-Medic Inc., Laboratory Corporation of America, Lifecodes Corporation, LipoScience Inc., Litholink Corporation, MEDTOX Scientific Inc., MNG Laboratories, MedAxio Insurance Medical Services GP Inc., MedAxio Insurance Medical Services LP, Medical Neurogenitics LLC, Medtox Diagnostics Inc., Medtox Laboratories Inc., Monogram Biosciences Inc., Monogram Biosciences UK Limited, Myriad Autoimmune’s Vectra Testing Business, NWT Inc., National Genetics Institute, New Brighton Business Center LLC, New Imaging Diagnostics LLC, New Molecular Diagnostics Ventures LLC, Orchid Cellmark ULC, Ovia Health, PA Labs Inc., Paclab LLC, Path Lab Incorporated, Pathology Associates Medical Lab LLC, Pee Dee Pathology Associates Inc., Personal Genome Diagnostics Inc., Persys Technology Inc., Pixel by LabCorp, Princeton Diagnostic Laboratories of America Inc., Protedyne Corporation, SW/DL LLC, Saint Josephs-PAML LLC, Sequenom Biosciences (India) Pvt. Ltd., Sequenom Inc, Sequenom Inc., Tandem Labs Inc., Toxikon Corporation, Tri-Cities Laboratory LLC, Viro-Med Laboratories Inc., Visiun, and Yakima Medical Arts Inc.. Read More

Laboratory Co. of America Stock Price, News & Analysis (NYSE:LH)

$218.97

+2.06 (+0.95%)

(As of 12/1/2023 ET)

Compare

Today's Range: $216.69
▼
$219.78
50-Day Range: $197.69
▼
$218.95
52-Week Range: $174.20
▼
$222.33

Volume: 840,951 shs
Average Volume: 728,970 shs
Market Capitalization: $18.59 billion

P/E Ratio: 29.27
Dividend Yield: 1.32%
Price Target: $243.67

Laboratory Co. of America MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 11.3% Upside
$243.67 Price Target
Short Interest: Healthy
3.64% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: -0.66
Upright™ Environmental Score
News Sentiment: 1.54
Based on 3 Articles This Week
Insider Trading: Selling Shares
$291,623 Sold Last Quarter
Proj. Earnings Growth: 7.07%
From $13.57 to $14.53 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.30 out of 5 stars

Medical Sector

11th out of 951 stocks

Medical Laboratories Industry

1st out of 23 stocks

3.4

Analyst's Opinion

Consensus Rating
Laboratory Co. of America has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $243.67, Laboratory Co. of America has a forecasted upside of 11.3% from its current price of $218.97.
Amount of Analyst Coverage
Laboratory Co. of America has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
3.64% of the float of Laboratory Co. of America has been sold short.
Short Interest Ratio / Days to Cover
Laboratory Co. of America has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Laboratory Co. of America has recently decreased by 6.10%, indicating that investor sentiment is improving significantly.

2.5

Dividend Strength

Dividend Yield
Laboratory Co. of America pays a meaningful dividend of 1.35%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Laboratory Co. of America does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Laboratory Co. of America is 38.50%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Laboratory Co. of America will have a dividend payout ratio of 19.82% next year. This indicates that Laboratory Co. of America will be able to sustain or increase its dividend.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Laboratory Co. of America has received a 60.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Private clinical drug testing", "Private oncology diagnostics services", and "Private medical laboratory services" products. See details.
Environmental Sustainability
The Environmental Impact score for Laboratory Co. of America is -0.66.

3.6

News and Social Media Coverage

News Sentiment
Laboratory Co. of America has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Laboratory Co. of America this week, compared to 6 articles on an average week.
Search Interest
5 people have searched for LH on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
MarketBeat Follows
6 people have added Laboratory Co. of America to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Laboratory Co. of America insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $291,623.00 in company stock.
Percentage Held by Insiders
Only 0.65% of the stock of Laboratory Co. of America is held by insiders.
Percentage Held by Institutions
89.37% of the stock of Laboratory Co. of America is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Laboratory Co. of America are expected to grow by 7.07% in the coming year, from $13.57 to $14.53 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Laboratory Co. of America is 29.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.54.
Price to Earnings Ratio vs. Sector
The P/E ratio of Laboratory Co. of America is 29.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.37.
Price to Book Value per Share Ratio
Laboratory Co. of America has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Laboratory Co. of America Stock (NYSE:LH)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications to enable patients to check test results; and online applications for MCOs and accountable care organizations; and end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves MCOs, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

LH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LH Stock News Headlines

December 2, 2023 | seekingalpha.com

Laboratory Corporation: Multiple Updates, Same Investment Conclusion

November 24, 2023 | finance.yahoo.com

Labcorp (LH) Closes the Legacy Health Asset Acquisition Deal

December 3, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 21, 2023 | finance.yahoo.com

Laboratory Corporation of America Holdings: Reiterating HOLD

November 17, 2023 | markets.businessinsider.com

7 Analysts Have This to Say About Laboratory Corp

November 16, 2023 | finance.yahoo.com

Tigerlily Foundation and Labcorp Launch I AM INCLUDED Framework to Increase Clinical Trial Diversity, Accelerate Delivery of Innovative Cancer Treatments

November 8, 2023 | finance.yahoo.com

Ovia Health Unveils New Fertility and Family Building Benefit

November 6, 2023 | finance.yahoo.com

Laboratory Corp of America Holdings's Dividend Analysis

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

October 31, 2023 | marketwatch.com

Laboratory Corp. of America Holdings stock falls Monday, underperforms market

October 31, 2023 | finance.yahoo.com

The Laboratory Corp of America Holdings (LH) Company: A Short SWOT Analysis

October 28, 2023 | finance.yahoo.com

Laboratory Corporation of America Holdings (NYSE:LH) Q3 2023 Earnings Call Transcript

October 27, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Laboratory (LH) and Align Tech (ALGN)

October 27, 2023 | finance.yahoo.com

Laboratory Corporation of America Holdings: LabCorp Earnings: Solid Underlying Nonpandemic Test Demand Offsets Declines in COVID Tests

October 27, 2023 | finance.yahoo.com

Q3 2023 Laboratory Corporation of America Holdings Earnings Call

October 26, 2023 | seekingalpha.com

Laboratory Corporation of America Holdings (LH) Q3 2023 Earnings Conference Call Transcript

October 26, 2023 | finanznachrichten.de

Laboratory Corporation of America Holdings: Labcorp Announces 2023 Third Quarter Results

October 26, 2023 | msn.com

Labcorp (LH) Surpasses Q3 Earnings and Revenue Estimates

October 26, 2023 | finance.yahoo.com

Labcorp beats quarterly profit estimates on strength in routine testing segment

October 26, 2023 | finance.yahoo.com

Laboratory Corp of America Holdings (LH) Reports Q3 2023 Earnings

October 26, 2023 | seekingalpha.com

Laboratory Corporation of America Holdings 2023 Q3 - Results - Earnings Call Presentation

October 17, 2023 | finance.yahoo.com

Starboard Takes 5%-Plus Stake in Contract-Research Firm Fortrea

October 11, 2023 | finance.yahoo.com

Labcorp launches 3-part blood test for Alzheimer's

October 11, 2023 | finance.yahoo.com

Labcorp Launches New Test to Accelerate Path to Diagnosis of Alzheimer's Disease

October 4, 2023 | finance.yahoo.com

LABCORP AND BAYSTATE HEALTH ANNOUNCE STRATEGIC RELATIONSHIP FOR DIAGNOSTIC LABORATORY SERVICES

September 29, 2023 | finance.yahoo.com

Labcorp to Announce Third Quarter Financial Results on October 26, 2023

September 27, 2023 | finance.yahoo.com

Graves Gilbert, Circuit Clinical, and Labcorp Join Forces to Bring Clinical Trials to Patients across South Central Kentucky

See More Headlines

Receive LH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Laboratory Co. of America and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/8 Dividend: 8/07/2023
Dividend Payable: 9/08/2023
Last Earnings: 10/26/2023
Ex-Dividend for 12/12 Dividend: 11/07/2023
Today: 12/02/2023
Dividend Payable: 12/12/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/15/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Medical laboratories
Sub-Industry: Health Care Services
Sector: Medical
Current Symbol: NYSE:LH
Previous Symbol: NYSE:LH?
CUSIP: 50540R40
CIK: 920148
Web: www.labcorp.com
Phone: (336) 229-1127
Fax: 336-513-4510
Employees: 80,000
Year Founded: 1995

Price Target and Rating

Average Stock Price Target: $243.67
High Stock Price Target: $270.00
Low Stock Price Target: $210.00
Potential Upside/Downside: +11.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $7.48
Trailing P/E Ratio: 29.27
Forward P/E Ratio: 16.14
P/E Growth: N/A
Net Income: $1.28 billion
Net Margins: 4.88%
Pretax Margin: 7.30%
Return on Equity: 14.09%
Return on Assets: 6.97%

Debt

Debt-to-Equity Ratio: 0.57
Current Ratio: 1.36
Quick Ratio: 1.20

Sales & Book Value

Annual Sales: $15.07 billion
Price / Sales: 1.23
Cash Flow: $31.10 per share
Price / Cash Flow: 7.04
Book Value: $92.73 per share
Price / Book: 2.36

Miscellaneous

Outstanding Shares: 84,900,000
Free Float: 84,348,000
Market Cap: $18.59 billion
Optionable: Optionable
Beta: 1.07

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Adam H. Schechter (Age 58)
President, CEO & Chairman
Comp: $3.72M
Mr. Glenn A. Eisenberg (Age 62)
CFO & Executive VP
Comp: $1.54M
Mr. Mark S. Schroeder (Age 62)
Executive VP, President of Diagnostics Laboratories & COO
Comp: $1.06M
Dr. Brian J. Caveney J.D. (Age 49)
M.D., M.P.H., EVP, President of Early Development Research Laboratories & Chief Medical Officer
Comp: $1.22M
Mr. Peter J. Wilkinson (Age 51)
Senior VP & Chief Accounting Officer
Mr. Lance V. Berberian (Age 60)
Executive VP and Chief Information & Technology Officer
Comp: $876.62k
Dr. Marcia T. Eisenberg Ph.D. (Age 64)
Chief Scientific Officer & Senior VP
Christin O'Donnell
Vice President of Investor Relations
Ms. Sandra D. van der Vaart (Age 63)
Executive VP, Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Ms. Amy B. Summy (Age 56)
Executive VP & Chief Marketing Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Laboratory Co. of America Stock? LH Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Laboratory Co. of America was last updated on Tuesday, November 28, 2023 at 10:34 PM.

Pros

Here are some ways that investors could benefit from investing in Laboratory Co. of America Holdings:

The recent developments in Laboratory Co. of America Holdings have shown strong growth potential, making it an attractive investment option.
Laboratory Co. of America Holdings has a solid financial position, with consistent revenue and earnings growth over the past year.
The company's latest product offerings have received positive feedback from customers, indicating a strong demand in the market.
Laboratory Co. of America Holdings has a competitive advantage in the industry, with a strong market presence and a wide range of services.
The current stock price of Laboratory Co. of America Holdings is favorable, providing an opportunity for potential investors to enter at an attractive valuation.

Cons

Investors should be bearish about investing in Laboratory Co. of America Holdings for these reasons:

The recent market volatility and uncertainty may impact the performance of Laboratory Co. of America Holdings, leading to potential risks for investors.
Laboratory Co. of America Holdings operates in a highly regulated industry, which may result in increased compliance costs and potential legal risks.
There is a possibility of increased competition in the market, which could put pressure on Laboratory Co. of America Holdings' market share and profitability.
Changes in healthcare policies and regulations could have an adverse impact on Laboratory Co. of America Holdings' business operations and financial performance.
Investors should carefully consider their investment objectives and risk tolerance before investing in Laboratory Co. of America Holdings, as the stock market can be volatile and unpredictable.

LH Stock Analysis - Frequently Asked Questions

Should I buy or sell Laboratory Co. of America stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LH shares.
View LH analyst ratings or view top-rated stocks.
What is Laboratory Co. of America's stock price target for 2024?: 10 analysts have issued 12-month price targets for Laboratory Co. of America's shares. Their LH share price targets range from $210.00 to $270.00. On average, they predict the company's share price to reach $243.67 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price.
View analysts price targets for LH or view top-rated stocks among Wall Street analysts.
How have LH shares performed in 2023?: Laboratory Co. of America's stock was trading at $235.48 at the beginning of the year. Since then, LH stock has decreased by 7.0% and is now trading at $218.97.
View the best growth stocks for 2023 here.
Are investors shorting Laboratory Co. of America?: Laboratory Co. of America saw a decline in short interest during the month of October. As of October 31st, there was short interest totaling 3,280,000 shares, a decline of 14.4% from the October 15th total of 3,830,000 shares. Based on an average trading volume of 833,500 shares, the short-interest ratio is currently 3.9 days. Approximately 3.9% of the shares of the company are sold short.
View Laboratory Co. of America's Short Interest.
When is Laboratory Co. of America's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our LH earnings forecast.
How were Laboratory Co. of America's earnings last quarter?: Laboratory Co. of America Holdings (NYSE:LH) posted its quarterly earnings results on Thursday, October, 26th. The medical research company reported $3.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.37 by $0.01. The medical research company earned $3.06 billion during the quarter, compared to analyst estimates of $2.99 billion. Laboratory Co. of America had a trailing twelve-month return on equity of 14.09% and a net margin of 4.88%. The company's revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $4.68 earnings per share.
Read the conference call transcript.
How often does Laboratory Co. of America pay dividends? What is the dividend yield for Laboratory Co. of America?: Laboratory Co. of America declared a quarterly dividend on Thursday, October 12th. Shareholders of record on Wednesday, November 8th will be paid a dividend of $0.72 per share on Tuesday, December 12th. This represents a $2.88 annualized dividend and a yield of 1.32%. The ex-dividend date is Tuesday, November 7th.
Read our dividend analysis for LH.
Is Laboratory Co. of America a good dividend stock?: Laboratory Co. of America (NYSE:LH) pays an annual dividend of $2.88 per share and currently has a dividend yield of 1.35%. The dividend payout ratio is 38.50%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LH will have a dividend payout ratio of 19.82% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LH.

What ETFs hold Laboratory Co. of America's stock?: ETFs with the largest weight of Laboratory Co. of America (NYSE:LH) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), Cambiar Aggressive Value ETF (CAMX), Global X Telemedicine & Digital Health ETF (EDOC), iShares U.S. Healthcare Providers ETF (IHF), VictoryShares THB Mid Cap ESG ETF (MDCP), BlackRock Large Cap Value ETF (BLCV), Strategas Global Policy Opportunities ETF (SAGP) and Thrivent Small-Mid Cap ESG ETF (TSME).
What guidance has Laboratory Co. of America issued on next quarter's earnings?: Laboratory Co. of America updated its FY 2026 earnings guidance on Friday, September, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $14.00B-.
What is Adam Schechter's approval rating as Laboratory Co. of America's CEO?: 143 employees have rated Laboratory Co. of America Chief Executive Officer Adam Schechter on Glassdoor.com. Adam Schechter has an approval rating of 73% among the company's employees.
What other stocks do shareholders of Laboratory Co. of America own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Co. of America investors own include Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Pfizer (PFE), Johnson & Johnson (JNJ), NVIDIA (NVDA), Abbott Laboratories (abt), AbbVie (ABBV), Alibaba Group (BABA) and Amgen (AMGN).
Who are Laboratory Co. of America's major shareholders?: Laboratory Co. of America's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (2.93%), Morgan Stanley (2.61%), Lazard Asset Management LLC (2.61%), Diamond Hill Capital Management Inc. (1.51%), Northern Trust Corp (1.33%) and FMR LLC (1.26%). Insiders that own company stock include Amy B Summy, Brian J Caveney, Der Vaart Sandra D Van, Dwight Gary Gilliland, Glenn A Eisenberg, Jean-Luc Belingard, Kerrii B Anderson, Mark S Schroeder, Paul R Kirchgraber, Peter J Wilkinson, Peter M Neupert and R Sanders Williams.
View institutional ownership trends.
How do I buy shares of Laboratory Co. of America?: Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Laboratory Co. of America have any subsidiaries?: The following companies are subsidiares of Laboratory Co. of America: 1957285 Ontario Inc. dba Quality Underwriting Services, 2089729 Ontario Inc., 2248848 Ontario Inc., 3065619 Nova Scotia Company, 3257959 Nova Scotia Company, 8165335 Canada Inc., 8348596 Canada Inc., 896988 Ontario Limited, 9279-3280 Quebec Inc., Accupath Diagnostic Laboratories Inc., Assets of Pathology Inc, Beacon LBS IPA Inc., Beacon Laboratory Benefit Solutions Inc., CannAmm GP Inc., CannAmm Limited Partnership, Center for Disease Detection International, Center for Disease Detection LLC, Centrex Clinical Laboratories Inc., Chiltern, Clearstone Central Laboratories (U.S.) Inc., Clearstone Holdings (International) Ltd., Clinical Outreach Laboratory Services, Clipper Holdings Inc., Colorado Coagulation Consultants Inc., Colorado Laboratory Services LLC, Correlagen Diagnostics Inc., Covance Inc., Curalab Inc., Cytometry Associates Inc., Czura Thornton (Hong Kong) Limited, DCL Acquisition Inc., DCL Medical Laboratories LLC, DCL Sub LLC, DIANON Systems Inc., DL Holdings Limited Partnership, Decision Diagnostics L.L.C. (aka DaVinici/Medicorp LLC), Diagnostic Services Inc., DynaLifeDX, Dynacare - Gamma Laboratory Partnership, Dynacare Company, Dynacare G.P. Inc., Dynacare Holdco LLC, Dynacare Laboratories Inc., Dynacare Laboratories Limited Partnership, Dynacare Northwest Inc., Dynacare Realty Inc., DynalifeDX Infrastructure Inc., Envigo's nonclinical contract research services business, Esoterix Genetic Counseling LLC, Esoterix Genetic Laboratories LLC, Esoterix Inc., Execmed Health Services Inc., FirstSource Laboratory Solutions Inc., GDML Medical Laboratories Inc, Gamma Dynacare Central Medical Laboratories GP Inc., Gamma Dynacare Central Medical Laboratory Limited Partnership, HHLA Lab-In-An-Envelope LLC, Health Testing Centers Inc., Health Trans Services Inc., Home Healthcare Laboratory of America LLC, IDX Pathology Inc., Impact Genetics Corporation, Impact Genetics Inc., Kaleida LabCorp LLC, Lab Delivery Service of New York City Inc., LabCorp BVBA, LabCorp Belgium Holdings Inc., LabCorp Central Laboratories (Canada) Inc., LabCorp Central Laboratories (China) Inc., LabCorp Colorado Inc., LabCorp Development Company, LabCorp Employer Services Inc., LabCorp Health System Diagnostics LLC, LabCorp Indiana Inc., LabCorp Japan G.K., LabCorp Limited, LabCorp Michigan Inc., LabCorp Nebraska Inc., LabCorp Neon Ltd., LabCorp Neon Switzerland S.à.r.l., LabCorp Specialty Testing Billing Service Inc., LabCorp Specialty Testing Group Inc., LabCorp Staffing Solutions Inc., LabCorp Tennessee LLC, LabCorp UK Holdings Ltd., LabWest Inc., Laboratoire Bio-Medic Inc., Laboratory Corporation of America, Lifecodes Corporation, LipoScience Inc., Litholink Corporation, MEDTOX Scientific Inc., MNG Laboratories, MedAxio Insurance Medical Services GP Inc., MedAxio Insurance Medical Services LP, Medical Neurogenitics LLC, Medtox Diagnostics Inc., Medtox Laboratories Inc., Monogram Biosciences Inc., Monogram Biosciences UK Limited, Myriad Autoimmune’s Vectra Testing Business, NWT Inc., National Genetics Institute, New Brighton Business Center LLC, New Imaging Diagnostics LLC, New Molecular Diagnostics Ventures LLC, Orchid Cellmark ULC, Ovia Health, PA Labs Inc., Paclab LLC, Path Lab Incorporated, Pathology Associates Medical Lab LLC, Pee Dee Pathology Associates Inc., Personal Genome Diagnostics Inc., Persys Technology Inc., Pixel by LabCorp, Princeton Diagnostic Laboratories of America Inc., Protedyne Corporation, SW/DL LLC, Saint Josephs-PAML LLC, Sequenom Biosciences (India) Pvt. Ltd., Sequenom Inc, Sequenom Inc., Tandem Labs Inc., Toxikon Corporation, Tri-Cities Laboratory LLC, Viro-Med Laboratories Inc., Visiun, and Yakima Medical Arts Inc..
Read More

This page (NYSE:LH) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial